Celldex Therapeutics (CLDX) Long-Term Debt Repayments (2011)
Celldex Therapeutics (CLDX) posted quarterly Long-Term Debt Repayments of $12.5 million for Q1 2011.
Analysis
Celldex Therapeutics (CLDX) Long-Term Debt Repayments (2011) Analysis & Trends
Celldex Therapeutics' Long-Term Debt Repayments history runs 1 years deep, the most recent figure standing at $12.5 million for Q1 2011.
- In Q1 2011, Long-Term Debt Repayments changed N/A year-over-year to $12.5 million; the TTM figure through Dec 2011 stood at $12.5 million (changed N/A YoY), while the FY2011 annual figure was $12.5 million, changed N/A from the prior year.
- Long-Term Debt Repayments for Q1 2011 stood at $12.5 million.
- The five-year high for Long-Term Debt Repayments was $12.5 million in Q1 2011, with the low at $12.5 million in Q1 2011.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 17.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 10 | Celldex Therapeutics | 3.08 Bn | 3.08 Bn | -2.57 Mn | - |